The use of medetomidine-based sedation protocols to perform urohydropropulsion and cystoscopy in the dog.

Voiding urohydropropulsion and cystoscopy are routine procedures performed in the dog for diagnostic and therapeutic purposes. These procedures are typically performed under general anesthesia. The purpose of this study was to describe the use of medetomidine-based sedation protocols to perform voiding urohydropropulsion and cystoscopy in cardiovascularly healthy, non-diabetic dogs without evidence of urinary obstruction, renal disease, or hepatic disease. Results of this study revealed significantly shorter procedure times and decreased cost in sedated dogs, with diagnostic and therapeutic outcomes equivalent to those of patients that underwent general anesthesia. Based on the results of this retrospective study, the authors recommend medetomidine-based sedation protocols for voiding urohydropropulsion and cystoscopy in appropriately selected patients.

Usage des protocoles de sédation à la médétomidine pour réaliser l'urohydropropulsion et la cystoscopie chez un chien. L'urohydropropulsion permictionnelle et la cystoscopie sont des interventions de routine réalisées chez le chien à des fins diagnostiques et thérapeutiques. Ces interventions sont habituellement réalisées sous anesthésie générale. Le but de cette étude était de décrire l'usage des protocoles de sédation à la médétomidine afin d'effectuer l'urohydropropulsion permictionnelle et la cystoscopie chez des chiens en bonne santé cardiovasculaire et non diabétiques sans signe d'obstruction urinaire, de maladie rénale ni de maladie hépatique. Les résultats de cette étude ont révélé des temps d'intervention significativement réduits et une baisse du coût chez les chiens sous sédation, avec des résultats diagnostiques et thérapeutiques équivalant à ceux de patients qui avaient subi une anesthésie générale. Selon les résultats de cette étude rétrospective, les auteurs recommandent des protocoles de sédation à la médétomidine pour l'urohydropropulsion permictionnelle et la cystoscopie chez les patients choisis selon des critères appropriés.(Traduit par Isabelle Vallières).

Response of hypotensive dogs to dopamine hydrochloride and dobutamine hydrochloride during deep isoflurane anesthesia.

OBJECTIVE: To evaluate the dose-related cardiovascular and urine output (UrO) effects of dopamine hydrochloride and dobutamine hydrochloride, administered individually and in combination at various ratios, and identify individual doses that achieve target mean arterial blood pressure (MAP; 70 mm Hg) and cardiac index (CI; 150 mL/kg/min) in dogs during deep isoflurane anesthesia. ANIMALS: 10 young clinically normal dogs. PROCEDURES: Following isoflurane equilibration at a baseline MAP of 50 mm Hg on 3 occasions, dogs randomly received IV administration of dopamine (3, 7, 10, 15, and 20 microg/kg/min), dobutamine (1, 2, 4, 6, and 8 microg/kg/min), and dopamine-dobutamine combinations (3.5:1, 3.5:4, 7:2, 14:1, and 14:4 microg/kg/min) in a crossover study. Selected cardiovascular and UrO effects were determined following 20-minute infusions at each dose. RESULTS: Dopamine caused significant dose-dependent responses and achieved target MAP and CI at 7 microg/kg/min; dobutamine at 2 microg/kg/min significantly affected only CI values. At any dose, dopamine significantly affected UrO, whereas dobutamine did not. Target MAP and CI values were achieved with a dopamine-dobutamine combination at 7:2 microg/kg/min; a dopamine-related dose response for MAP and dopamine- and dobutamine-related dose responses for CI were identified. Changes in UrO were associated with dopamine only. CONCLUSIONS AND CLINICAL RELEVANCE: In isoflurane-anesthetized dogs, a guideline dose for dopamine of 7 microg/kg/min is suggested; dobutamine alone did not improve MAP. Data regarding cardiovascular and UrO effects indicated that the combination of dopamine and dobutamine did not provide greater benefit than use of dopamine alone in dogs.